ATOSSA THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $21.2M | $14.1M | $17.3M | $15.1M | $9.2M |
| Operating expenses | $37.1M | $27.6M | $31.4M | $27.7M | $20.5M |
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M |
| Pretax income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M |
| Balance Sheet | |||||
| Cash and equivalents | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M |
| Current assets | $45.6M | $74.5M | $92.2M | $118.2M | $141.2M |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M |
| Current liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M |
| Stockholders' equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M |
| Depreciation and amortization | $16,000 | $17,000 | $23,000 | $8,000 | $23,000 |
| Stock-based compensation | $2.6M | $2.3M | $4.6M | $6.8M | $5.3M |
| Capital expenditure | $23,000 | $19,000 | $14,000 | $27,000 | $9,000 |
| Free cash flow | -$29.8M | -$21.0M | -$21.0M | -$20.8M | -$16.5M |
| Share repurchases | — | $0 | $1.5M | $0 | — |
| Impairments | — | — | — | — | $0 |
Shares outstanding 8.6M · Free float 31.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.